Characteristics associated with common reasons to pursue genomic profiling among patients with metastatic genitourinary cancers.
Malhotra J, Philip E, Govindarajan A, Salgia S, Meza L, Zengin Z, Muddasani R, Chawla N, Castro D, Chehrazi-Raffle A, Dizman N, Bergerot P, Hsu J, Dorff T, Pal S, Bergerot C. Characteristics associated with common reasons to pursue genomic profiling among patients with metastatic genitourinary cancers. Journal Of Clinical Oncology 2022, 40: 327-327. DOI: 10.1200/jco.2022.40.6_suppl.327.Peer-Reviewed Original ResearchPhysician indicationGenitourinary cancersTreatment responseCommon reasonAdvanced genitourinary cancersMetastatic genitourinary cancerGenomic profiling testsCross-sectional studyEffective provider communicationChart reviewOlder patientsPatient characteristicsYounger patientsClinicopathologic characteristicsPatients' perceptionsProvider communicationPatient responsePatientsOlder ageGenomic profilingLow levelsCancerImportant associationProfiling testsGPsChanges in perception of immunotherapy over time among patients with advanced genitourinary cancers.
Malhotra J, Philip E, Govindarajan A, Meza L, Zengin Z, Salgia S, Muddasani R, Chawla N, Castro D, Chehrazi-Raffle A, Dizman N, Bergerot P, Hsu J, Dorff T, Pal S, Bergerot C. Changes in perception of immunotherapy over time among patients with advanced genitourinary cancers. Journal Of Clinical Oncology 2022, 40: 328-328. DOI: 10.1200/jco.2022.40.6_suppl.328.Peer-Reviewed Original ResearchAdvanced genitourinary cancersGenitourinary cancersExpectation of cureQuality of lifeSide effectsMetastatic genitourinary cancerProportion of patientsStart of therapyMajority of patientsMonths of treatmentRenal cell carcinomaSevere side effectsLongitudinal studyMedian ageClinical outcomesImmunotherapy treatmentCell carcinomaPatients' perceptionsImmunotherapyPatientsGreater efficacyTumor progressionCancerCancer treatmentTime points